MX2017004819A - Metodos de tratamiento de transtornos urológicos usando sarm. - Google Patents

Metodos de tratamiento de transtornos urológicos usando sarm.

Info

Publication number
MX2017004819A
MX2017004819A MX2017004819A MX2017004819A MX2017004819A MX 2017004819 A MX2017004819 A MX 2017004819A MX 2017004819 A MX2017004819 A MX 2017004819A MX 2017004819 A MX2017004819 A MX 2017004819A MX 2017004819 A MX2017004819 A MX 2017004819A
Authority
MX
Mexico
Prior art keywords
methods
sarms
urological disorders
treating urological
treating
Prior art date
Application number
MX2017004819A
Other languages
English (en)
Inventor
Narayanan Ramesh
Hesselberg Jeffrey
Ann Johnston Mary
H Getzenberg Robert
Original Assignee
Gtx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gtx Inc filed Critical Gtx Inc
Publication of MX2017004819A publication Critical patent/MX2017004819A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/28—Antiandrogens

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Gynecology & Obstetrics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se refiere a métodos de tratamiento, prevención, supervisión y/o inhibición de trastornos urológicos, como incontinencia urinaria que incluye incontinencia urinaria de esfuerzo y trastornos del piso pélvico por administración de un compuesto de SARM de la invención.
MX2017004819A 2014-10-16 2015-10-16 Metodos de tratamiento de transtornos urológicos usando sarm. MX2017004819A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462064817P 2014-10-16 2014-10-16
PCT/US2015/056063 WO2016061534A1 (en) 2014-10-16 2015-10-16 METHODS OF TREATING UROLOGICAL DISORDERS USING SARMs

Publications (1)

Publication Number Publication Date
MX2017004819A true MX2017004819A (es) 2018-06-12

Family

ID=55747451

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017004819A MX2017004819A (es) 2014-10-16 2015-10-16 Metodos de tratamiento de transtornos urológicos usando sarm.

Country Status (12)

Country Link
US (2) US20160106702A1 (es)
EP (1) EP3206675A4 (es)
JP (1) JP2017531012A (es)
KR (2) KR20190077607A (es)
CN (1) CN106999453A (es)
AU (1) AU2015331756A1 (es)
BR (1) BR112017007916A2 (es)
CA (1) CA2964371A1 (es)
IL (1) IL251587A0 (es)
MX (1) MX2017004819A (es)
RU (2) RU2019117364A (es)
WO (1) WO2016061534A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019003104A1 (en) * 2017-06-28 2019-01-03 Novartis Ag METHOD FOR PREVENTING AND TREATING URINARY INCONTINENCE
CN109761778A (zh) * 2018-12-10 2019-05-17 石家庄市度智医药科技有限公司 一种合成光学活性α-羟基丙酰胺衍生物的方法
CN111956640B (zh) * 2020-09-14 2022-07-15 长春金赛药业有限责任公司 含酯基芳香丙酰胺类化合物在制备治疗尿失禁药物中的应用
CN112641781B (zh) * 2021-01-08 2022-07-12 长春金赛药业有限责任公司 含酯基芳香丙酰胺的SARMs类化合物及其代谢物在制备抗新冠病毒药物中的应用
RU2755278C1 (ru) * 2021-01-26 2021-09-14 Александр Владимирович Чернов Цистоскопическое лечение гормонзависимой сфинктерной недостаточности мочевого пузыря у самок собак

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6376486B1 (en) * 2000-07-06 2002-04-23 American Home Products Corporation Methods of inhibiting sphincter incontinence
AU8523001A (en) * 2000-08-24 2002-03-04 Gtx Inc Selective androgen receptor modulators and methods of use thereof
US6998500B2 (en) * 2000-08-24 2006-02-14 University Of Tennessee Research Foundation Selective androgen receptor modulators and methods of use thereof
BR0215115A (pt) * 2001-12-06 2005-04-19 Gtx Inc Tratamento de perda muscular com moduladores de receptores de androgênio seletivos
US8853266B2 (en) * 2001-12-06 2014-10-07 University Of Tennessee Research Foundation Selective androgen receptor modulators for treating diabetes
BRPI0307699A2 (pt) * 2002-02-07 2015-06-16 Gtx Inc Tratamento de hiperplasia benigna da próstata com sarms.
KR101088352B1 (ko) * 2002-02-28 2011-11-30 유니버시티 오브 테네시 리서치 파운데이션 다치환된 선택적 안드로겐 수용체 조절자 및 이를 사용하는 방법
CA2501797A1 (en) * 2002-10-15 2004-04-29 Gtx, Inc. Treating obesity with selective androgen receptor modulators
US20140011774A1 (en) * 2002-12-05 2014-01-09 University Of Tennessee Research Foundation Selective androgen receptor modulators
FI20030958A0 (fi) * 2003-06-27 2003-06-27 Orion Corp Uusia yhdisteitä
CA2553609A1 (en) * 2004-01-15 2005-07-28 Mount Sinai Hospital Methods and compositions for modulating a steroid receptor
EP1725522B1 (en) * 2004-03-03 2014-09-10 GlaxoSmithKline LLC Aniline derivatives as selective androgen receptor modulators
PL1753417T3 (pl) * 2004-06-07 2012-09-28 Univ Tennessee Res Found Selektywny modulator receptora androgenowego i jego zastosowania medyczne
EP2248524A3 (en) * 2004-08-25 2011-03-09 Takeda Pharmaceutical Company Limited Preventives/remedies for stress urinary incontinence and method of screening the same
US9409856B2 (en) * 2005-11-28 2016-08-09 Gtx, Inc. Estrogen receptor ligands and methods of use thereof
US8546451B2 (en) * 2005-11-28 2013-10-01 Gtx, Inc. Estrogen receptor ligands and methods of use thereof
EA018066B1 (ru) * 2005-11-28 2013-05-30 Джи Ти Икс, ИНК. Агент, связывающийся с ядерными рецепторами
US8268806B2 (en) * 2007-08-10 2012-09-18 Endorecherche, Inc. Pharmaceutical compositions
US9969683B2 (en) * 2012-07-13 2018-05-15 Gtx, Inc. Method of treating estrogen receptor (ER)-positive breast cancers with selective androgen receptor modulator (SARMS)
LT2872482T (lt) 2012-07-13 2020-12-28 Oncternal Therapeutics, Inc. Krūties vėžių gydymo būdas selektyviu androgeno receptoriaus moduliatoriumi
IN2014KN02993A (es) * 2012-07-17 2015-05-08 Glaxosmithkline Ip No 2 Ltd
US9814698B2 (en) * 2015-04-21 2017-11-14 University Of Tennessee Research Foundation Selective androgen receptor degrader (SARD) ligands and methods of use thereof

Also Published As

Publication number Publication date
CA2964371A1 (en) 2016-04-21
EP3206675A1 (en) 2017-08-23
BR112017007916A2 (pt) 2018-01-23
KR20190077607A (ko) 2019-07-03
KR20170066642A (ko) 2017-06-14
US20160106702A1 (en) 2016-04-21
CN106999453A (zh) 2017-08-01
RU2691652C2 (ru) 2019-06-17
EP3206675A4 (en) 2018-07-11
RU2017116773A (ru) 2018-11-16
WO2016061534A1 (en) 2016-04-21
JP2017531012A (ja) 2017-10-19
US20180177755A1 (en) 2018-06-28
RU2019117364A (ru) 2019-08-05
IL251587A0 (en) 2017-06-29
KR101994922B1 (ko) 2019-07-01
AU2015331756A1 (en) 2017-05-04
RU2017116773A3 (es) 2018-11-16

Similar Documents

Publication Publication Date Title
MX2018003472A (es) Moduladores de la expresion de kras.
MX2022007436A (es) Inhibidores de la autotaxina y sus usos.
MX2018009773A (es) Heteroarilos inhibidores de peptidilarginina desiminasa 4 (pad4).
MX2016015862A (es) Compuestos inhibidores de la cinasa de union a tank.
SG10201808940WA (en) Nox inhibitor and nfкb inhibitor containing methoxyflavone
GEP20247593B (en) Compositions and methods of inhibiting masp-3 for the treatment of various diseases and disorders
MX2017000546A (es) Composiciones para el tratamiento del cancer mediante el uso de antagonistas de union al eje de pd-1 e inhibidores de mek.
MX2018006632A (es) Inhibidores biciclicos de peptidilarginina deiminasa 4 (pad4).
JO3466B1 (ar) مواد ضابطة لتترا هيدرو بيريدوبيرازينات من gpr6
MX2023004969A (es) Metodos para tratar y prevenir infeccion por c. difficile.
MX2018006700A (es) Inhibidores aza-bencimidazol de peptidilarginina desiminasa (pad4).
MX2018012902A (es) Composiciones y métodos para el tratamiento de trastornos de almacenamiento lisosomal y trastornos caracterizados por disfunción lisosomal.
PH12017500459A1 (en) Azetidinyloxyphenylpyrrolidine compounds
MX2017004808A (es) Combinaciones que comprenden siponimod y laquinimod para el tratamiento de la esclerosis multiple.
MX2017004819A (es) Metodos de tratamiento de transtornos urológicos usando sarm.
MX2016010973A (es) Compuestos de aminocarbonilcarbamato.
AU2018253600A1 (en) Dosage forms and therapeutic uses of l-4-chlorokynurenine
PH12015502032A1 (en) Azetidinyloxyphenylpyrrolidine compounds
MX2018009662A (es) Metodo y composicion farmaceutica para tratamiento de neurodegeneracion.
GEP20186920B (en) Halogenated quinazolinthf-amines as pde1 inhibitors
TW201611845A (en) Treatment and functional cure of HIV infection by monoclonal antibodies to CD4 mediating competitive HIV entry inhibition
WO2016069477A3 (en) A method of treating cancer that overexpresses topbp1
PH12015502637A1 (en) Benzothiophene compound
PH12016500824A1 (en) Compositions and methods for the treatment of viral diseases with pde4 modulators
MX2017005669A (es) Derivados de hidroxido de bencilo, preparacion de los mismos y uso terapeutico de los mismos.